Multidrug and Extensively Drug-Resistant Tuberculosis

Infectious Disease Clinics of North America - United Kingdom
doi 10.1016/j.idc.2019.09.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pharmacokinetics of Levofloxacin in Multidrug- And Extensively Drug-Resistant Tuberculosis Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

Transmission of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in a Metropolitan City

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2012English

Linezolid Safety, Tolerability and Efficacy to Treat Multidrug- And Extensively Drug-Resistant Tuberculosis

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2011English

Pre-Extensively Drug Resistant Tuberculosis (Pre-XDR-Tb) Among Pulmonary Multidrug Resistant Tuberculosis (MDR-TB) Patients in Bangladesh

Journal of Tuberculosis Research
2018English

Extensively Drug-Resistant Tuberculosis in South Africa

The Lancet
Medicine
2010English

The Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Dominant Incidence of Multidrug and Extensively Drug-Resistant Specific Mycobacterium Tuberculosis Clones in Osaka Prefecture, Japan

PLoS ONE
Multidisciplinary
2012English

Extensively Drug-Resistant Tuberculosis: Back to the Future

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

Pyrido[1,2-A]benzimidazole-Based Agents Active Against Tuberculosis (TB), Multidrug-Resistant (MDR) TB and Extensively Drug-Resistant (XDR) TB

ChemMedChem
Organic ChemistryMolecular MedicinePharmacologyBiochemistryToxicologyDrug DiscoveryPharmaceutics
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy